Cover Image

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis

Introduction: The CFTR modulator drug elexacaftor/tezacaftor/ivacaftor (ETI) was shown to improve CFTR function and clinical symptoms in patients with cystic fibrosis (CF) with at least one F508del allele. Recently, some case reports suggested potential side effects of ETI on mental health with an i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Linus Piehler (Author), Ralf Thalemann (Author), Christine Lehmann (Author), Stephanie Thee (Author), Jobst Röhmel (Author), Zulfiya Syunyaeva (Author), Mirjam Stahl (Author), Marcus A. Mall (Author), Simon Y. Graeber (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years
by: Julian Berges, et al.
Published: (2023)

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging
by: Lena Wucherpfennig, et al.
Published: (2023)

Comparison of Oropharyngeal Microbiota from Children with Asthma and Cystic Fibrosis
by: Sébastien Boutin, et al.
Published: (2017)

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
by: Olaf Sommerburg, et al.
Published: (2021)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023)

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024)

Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy
by: Frauke Stanke, et al.
Published: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor
by: Payal Patel, et al.
Published: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023)

Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
by: Katharina Schütz, et al.
Published: (2023)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
by: Mafalda Bacalhau, et al.
Published: (2023)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
by: Renate Kos, et al.
Published: (2022)

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor-Tezacaftor-Ivacaftor
by: Kimberly Tantuco, MD, et al.
Published: (2024)

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats
by: Nicole Reyne, et al.
Published: (2024)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
by: Libor Fila, et al.
Published: (2023)

Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
by: Wolfgang Gruber, et al.
Published: (2024)

Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together
by: Rachel Kinuani, et al.
Published: (2024)

Lung transplant list withdrawal in a liver transplant patient thanks to elexacaftor-tezacaftor-ivacaftor: a case report
by: Arianna Traunero, et al.
Published: (2024)

Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis
by: Anita Balázs, et al.
Published: (2018)

Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis
by: Rebecca H. Goldberg, BS, et al.
Published: (2021)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2022)

Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study
by: Insa Korten, et al.
Published: (2022)

Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor/tezacaftor/ivacaftor therapy in a pediatric patient with cystic fibrosis
by: Michael P. Coughlin, et al.
Published: (2024)

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis
by: Wenye Xu, et al.
Published: (2023)

Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
by: Sabine Dettmer, et al.
Published: (2023)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
by: Jochen G. Mainz, et al.
Published: (2023)

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study
by: Giuseppe Migliorisi, et al.
Published: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients
by: Eunjin Hong, et al.
Published: (2023)

Geographical Accessibility of Pediatric Inpatient, Nephrology, and Urology Services in Europe
by: Nicolas Terliesner, et al.
Published: (2020)

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire
by: Jochen G. Mainz, et al.
Published: (2023)

Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
by: Hisham Ibrahim, et al.
Published: (2023)

Acne vulgaris in a 22‐year‐old cystic fibrosis patient treated with Elexacaftor‐Tezacaftor‐Ivacaftor and good clinical response to isotretinoin-A case report
by: Isabelle Pfeiffer, et al.
Published: (2024)

Immune-mediated inflammatory diseases (IMIDs) in children: key research questions and some answers
by: Tilmann Kallinich, et al.
Published: (2024)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistryResearch in context
by: Sivagurunathan Sutharsan, et al.
Published: (2023)

Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study
by: Dorothea Appelt, et al.
Published: (2023)